Luminetx Inks Deal with Amerinet

MEMPHIS, Tenn. — Luminetx Corp. announced today it has signed a key three-year vendor contract with one of the countries premier Group Purchasing Organizations (GPO) Amerinet Inc., which represents the Memphis-based company's first group purchasing contract to date.
Through the deal, Amerinet's 24,000-plus member base, of which more than 2,000 are acute care institutions in nature, will have access to custom Amerinet group purchasing discounts as they relate to the VeinViewer by Luminetx(TM), the company's signature product. The vascular imaging system allows physicians, nurses and other health care professionals to clearly see accessible vasculature (or lack thereof) in real time. The device uses a combination of near-infrared light and patented technologies to image vascular structures and project their location directly on the surface of the skin. This provides clinicians with a safe, non-invasive adjunct technology for clinical treatments and procedures including, but not limited to: IV insertions, PICC line insertions, routine venipuncture (blood sampling), blood and plasma donations and treatment for varicose and spider veins.

full article >> http://www.centredaily.com/business/story/300547.html

LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer

BURLINGTON, Mass., Dec. 21 (HSMN NewsFeed) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT ), a provider of peripheral vascular devices and implants, yesterday acquired Biomateriali S.r.l., a privately held Italian vascular graft manufacturer, for euro 1.8 million in cash, the assumption of euro 0.8 million in intercompany liabilities, and contingent liabilities of euro 1.0 - euro 1.5 million. The acquisition was structured as a stock purchase.
Key attributes of Biomateriali:-- Biomateriali designs, manufactures, and markets straight and bifurcated polyester arterial prostheses. Polyester vascular grafts are used in a variety of arterial replacement and repair surgeries, predominantly open abdominal aortic aneurysm ("AAA") repair. Biomateriali has been manufacturing these prostheses under the "Albograft" brand for over 10 years.

Full text >>

Biosphere-DuPont Collaboration May Create Higher-Margin Microspheres

BioSphere Medical, which has an FDA approved method to treat symptomatic uterine fibroids using microsphere technology, has signed an agreement with DuPont Applied BioSciences to evaluate potential peripheral vascular and embolotherapy research, development, and manufacturing projects.

The agreement establishes a “non-binding framework” for the parties to consider and evaluate potential projects that target and deliver leading edge solutions in embolotherapy.

full article >> http://www.onemedplace.com/blog/archives/500

Merit Medical Announces 510(k) Notification For New Sea Dragon Torque Device

SOUTH JORDAN, Utah, Dec 20, 2007 (PrimeNewswire via COMTEX) -- Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology and radiology procedures, announced today that it has received notification from the FDA of 510(k) clearance for its new Sea Dragon torque device.

The Sea Dragon torque device is used specifically with hydrophilic guide wires. It was recently released in Europe and is being well received by physicians there.

press release >> http://www.foxbusiness.com/markets/industries/health-care/article/merit-medical-announces-510k-notification-new-sea-dragon-torque-device_415426_10.html

AngioDynamics Issues Radiofrequency Ablation Statement

AngioDynamics Issues Radiofrequency Ablation Statement

QUEENSBURY, N.Y.--(BUSINESS WIRE)--AngioDynamics (NASDAQ:ANGO), a leading provider of innovative medical devices used by interventional radiologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, today commented on the clinical studies on which the FDA based its December 11, 2007 Public Health Notification regarding the deaths associated with the use of radio frequency ablation of lung tumors. No AngioDynamics’ RITA radio frequency ablation (RF) probes were used in these studies.

AngioDynamics has conducted a 106 patient clinical trial, RAPTURE, involving the use of its RF technology to treat lung malignancies. The trial included patients from Europe, Australia and the United States. There were no deaths within 30 days of treatment. Further, the Company knows of no reported deaths in published studies in which AngioDynamics RF probes were used to treat a variety of lung tumors. The Company expects the RAPTURE clinical trial results to be published in the first half of 2008.

press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071219005759&newsLang=e

PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)

Trial designed to evaluate effectiveness of RenalGuard(TM) in preventing Contrast -Induced Nephropathy
FRANKLIN, Mass., Dec. 19 /PRNewswire-FirstCall/ -- PLC Systems Inc. , a company focused on innovative cardiac and vascular medical device-based technologies, announced today that it has named two lead investigators for the upcoming pivotal trial of its RenalGuard Therapy(TM). The lead investigators are Charles Davidson, MD, Professor of Medicine, Northwestern University Medical School and Richard J. Solomon, MD, Professor of Medicine, University of Vermont College of Medicine. The trial is designed as a multi-center, prospective, randomized controlled trial to evaluate the effect of RenalGuard(TM) in the prevention of Contrast-Induced Nephropathy (CIN) during cardiovascular and peripheral imaging procedures performed in a catheterization lab. PLC intends to begin enrollment in the RenalGuard Pivotal Trial in early 2008, following receipt of the necessary approval from the U.S. Food & Drug Administration.

full article >> http://money.cnn.com/news/newsfeeds/articles/prnewswire/NEW03119122007-1.htm

ev3 Introduces Two New Enhanced Offerings For the Treatment of Peripheral Artery Disease

The SilverHawk® LS-M and MS-M with proprietary MEC™ Technology increases tissue collection capacity, representing an important advancement in Above the Knee treatment of Peripheral Artery Disease
PLYMOUTH, Minn.--(BUSINESS WIRE)--ev3 Inc. (NASDAQ:EVVV), today announced the U.S. launch of the company’s most recent additions to the SilverHawk family of products: the SilverHawk® LS-M and MS-M. These devices are among the latest in plaque excision technology and are designed to treat lesions in arteries above the knee for patients suffering from peripheral artery disease (PAD).
The SilverHawk® LS-M and MS-M include MEC™ (Micro Efficient Compression) Technology, a novel advancement which features precision laser-drilled vent holes in the tip of the catheter. These micro vent holes release fluid pressure, providing more space for the collection of tissue in the tip of the device. This technology has the potential to reduce overall procedure time by enabling physicians to increase tissue collection during plaque removal procedures in large vessels above the knee. In vitro bench test results performed by the company have demonstrated up to a 30 percent increase in tissue capture per insertion compared to the previous device.
press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071218006190&newsLang=en

Ambulatory Services of America Acquires Innovative Dialysis Systems and Related Joint Ventures

NASHVILLE, Tenn., Dec. 18 /PRNewswire/ -- Ambulatory Services of America, Inc. (ASA) announced today that it has completed an acquisition of the assets of Innovative Dialysis Systems, Inc. (IDS) and interests in joint ventures that own and operate 35 dialysis programs in California, Ohio, Oregon, Wyoming and Guam. IDS, owned by Allen Fulmer and Jerry Green, has provided management services to the acquired dialysis programs prior to the transactions. In addition to the 35 programs in which ASA has acquired an interest, it will manage two other dialysis facilities that were previously managed by IDS. ASA did not disclose the terms of the transactions.

full article >> http://www.earthtimes.org/articles/show/news_press_release,244619.shtml

Microfabrica Introduces Set of Miniature 'Building Blocks' for Minimally-Invasive Medical Devices

1-mm turbine, miniaturized 'car jack,' and micro-chainmail demonstrate the company's ultra-precision EFAB manufacturing technology
VAN NUYS, Calif., Dec. 18, 2007 -- Microfabrica Inc. will introduce at Medical Design & Manufacturing West a set of highly-miniaturized 'building blocks' which designers of minimally-invasive medical devices can use to develop innovative new products. Water-powered turbines just over 1 mm in diameter which spin at 120,000 revolutions per minute, millimeter-scale 'car jack'-like expanders, ultra-flexible micro-chainmail metal fabric, micro-needles, miniature ratchets, hinges, slides, and springs, and multi-lumen metal shapes are among the building blocks to be featured. Enabled by the company's unique EFAB manufacturing technology, these building blocks - and devices based on them - will be on display in Booth 466, Hall E, Anaheim Convention Center, Anaheim, CA, January 29-31, 2008.

full article >> http://www.ereleases.com/pr/20071218003.html

BioSphere Medical Receives CE Mark Approval for Transarterial Chemoembolization Using HepaSphere™ Microspheres

ROCKLAND, Mass.--(BUSINESS WIRE)--BioSphere Medical, Inc. (NASDAQ: BSMD) (“BioSphere”), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that it has received CE Mark approval for Transarterial Chemoembolization (TACE) of Hepatocellular Carcinoma (HCC) using HepaSphere™ Microspheres (HepaSphere) and Doxorubicin. As a condition of the CE Mark approval, BioSphere will conduct a 100-patient, post-market registry study in 10-15 European centers. CE Mark approval denotes conformity with European standards for safety and allows certified devices to be placed in the market in European Union countries.

press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071218005648&newsLang=en

FlowCardia Launches Peripheral CROSSER Catheter Portfolio In US

Sunnyvale, CA - FlowCardia, Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), announced FDA 510(k) clearance and immediate U.S. launch of the CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization Catheters.
The three peripheral CROSSER Catheters are endovascular tools used by interventional radiologists, vascular surgeons and interventional cardiologists to cross CTOs to help restore blood flow to the lower legs. The CROSSER is a rapid exchange catheter delivered over standard .014" and .018" guidewires that utilizes high frequency vibration to cross CTOs allowing for subsequent debulking, balloon angioplasty and stent placement. The peripheral CROSSER Catheters were studied in the FlowCardia PATRIOT Trial.

full article >> http://www.medicaldesignonline.com/content/news/article.asp?docid=%7B53E6B130-8A54-4C63-AB31-059A4C2A6828%7D&VNETCOOKIE=NO

Medtronic Starts First Human Study of Endurant™ Stent Graft System for Treatment of Abdominal Aortic Aneurysm

MINNEAPOLIS – Dec. 17, 2007 – Marking a major step toward expanding minimally invasive endovascular therapies, Medtronic, Inc. (NYSE: MDT), today announced the start of the first human study of its Endurant Stent Graft System, an investigational treatment for abdominal aortic aneurysm (AAA). The study supports Medtronic’s goal of providing physicians with a greater variety of solutions for treating patients with AAA – a dangerous bulge or weakness in the body’s main artery that can rupture with fatal consequences if left untreated. The company’s AAA stent graft portfolio currently includes the AneuRx AAAdvantage® platform in the United States and the Talent™ AAA platform outside the United States. The Endurant Stent Graft System’s highly flexible features and lower delivery profile are designed to improve conformability and trackability in tortuous aneurysmal anatomies.

full article >> http://pressmediawire.com/article.cfm?articleID=4301

BioForm Medical shares soar

NEW YORK, Dec 18, 2007 (Thomson Financial via COMTEX) -- BFRM charts news PowerRating -- Shares of BioForm Medical Inc. skyrocketed Monday after CIBC World Markets initiated coverage of the company with a sector outperformer rating and a $12 price range because of the company's anticipated success with new wrinkle-filler product Radiesse.
The shares rose 31.2% to $7.61.
BioForm also has in its pipeline a superficial treatment for varicose veins, Aethoxysklerol, which should get approval from the Food and Drug Administration before the end of 2009, CIBC said.

Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC

VANCOUVER, Dec. 17 (HSMN NewsFeed) - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration (FDA) for its innovative, anti-infective 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC).
"We are pleased to complete the submission of a 510(k) application to the FDA for our 5-FU CVC, as we believe this represents another important step towards commercializing this product line and developing our 5-FU anti-infective platform," said Dr. William Hunter, President and CEO of Angiotech.Pending the receipt of all necessary regulatory approvals, Angiotech anticipates launching the commercial 5-FU CVC product line in 2008.

Full text >>

Devax, Inc. Calls Off IPO

Medical device company Devax, Inc on Thursday filed to withdraw plans for an initial public offering, stating that such a move was "no longer in its best interests." Devax originally filed for an IPO in May of 2007, saying in a filing with the SEC that it is looking to raise up to $85M in an IPO on the Nasdaq Global Market.
Devax, originally founded in 1999 to develop a bare metal stent, is now developing the AXXESS Plus, designed specifically for deviating vessels. In 2005, the AXXESS Plus Stent was the first to show clinical results with a drug eluting stent designed specifically for bifurcation lesions.

AMAG Pharmaceuticals, Inc. Announces Presentation of Positive Results from Phase III Studies of Feru

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today announced positive results from pooled data from three open-label, multicenter, randomized Phase III trials of ferumoxytol as an intravenous iron replacement therapeutic. The data is being presented today at approximately 6:00 pm ET as a poster at the 49th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia. The poster is available on the Company’s web site at www.amagpharma.com.
The poster, “Treatment of Iron-Deficiency Anemia with IV Ferumoxytol in CKD Patients: Efficacy Compared with Oral Iron across Different Age Groups” presents results from 885 dialysis dependent and non-dialysis dependent patients with chronic kidney disease (CKD). Patients received either two doses of 510 mg of intravenous (IV) ferumoxytol within one week or 200 mg of oral iron daily for three weeks and were followed for 35 days. The pooled data demonstrated a statistically significant achievement of the primary endpoint in patients treated with ferumoxytol compared to those treated with oral iron.

full article >> http://www.pr-usa.net/index.php?option=com_content&task=view&id=51212&Itemid=9

AngioTech To Conduct Clinical Trials for VaxSys Vascular Wrap

Vascular access is a necessary procedure for patients with End Stage Renal Disease (ESRD) who will undergo hemodialysis. However, it is estimated that up to 50% of vascular accesses with grafts require repair within one year resulting in significant inconvenience and cost to the patient. Fortunately, new treatment options are being developed to make a vascular access last longer, but your help is needed.
Doctors are now conducting an investigational medical research study evaluating the effectiveness of an investigational product called VaxSys Vascular Wrap™ (also called "Vascular Wrap™). When used in conjunction with a vascular graft to create a vascular access for hemodialysis, it is believed that VaxSys Vascular Wrap™ may aid in making the vascular access last longer before repair is necessary by a physician.

information on the study >> http://www.vascularwraptrial.com/

New Statement on Safety of MRI With CV Devices

The American Heart Association has published a scientific statement on the safety of magnetic resonance imaging (MRI) in patients with cardiovascular devices, which has also been endorsed by the American College of Cardiology, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance [1]. The document states that for most devices, if there is a good clinical indication for an MRI scan, then the benefits probably outweigh the risks. Lead author Dr Glenn N Levine (Baylor College of Medicine, Houston, TX) told heartwire: "This is the first document that specifically addresses these issues." He explained that, over the years, decisions have been made about when it is safe to do an MRI scan with a particular device, but these have not been based for the most part on any good evidence. "When coronary stents first came out, for example, it was decided that you had to wait a minimum of six weeks before doing an MRI scan, but that was not based on any firm data. And there are still people out there who won't do an MRI ever in a patient with a stent, and that is absurd. We wanted to make recommendations that are in line with actual data and expert opinion."

full article >> http://www.abkhazia.com/content/view/1087/74/

Hatch Medical and Phase One Medical Sign Brokerage Agreement

2007 DEC 20 - (NewsRx.com) -- Hatch Medical, L.L.C., a medical device incubator and technology brokerage firm and Phase One Medical, L.L.C., a medical device research and development company announced that they have recently entered into an agreement for Hatch Medical to broker Phase One Medical's patented medical device anchoring technology platforms, Fusion(TM) and Tissue Clip(TM) (see also Thrombosis).
The medical device anchoring platforms utilize shape memory alloy's and proprietary design elements which can be integrated into implantable medical devices improving fixation and security of the implant. Phase One's unique anchoring systems provide bi-directional migration resistance and are not dependant on radial force for fixation unlike hooks and barbs which are used in many implanted devices today. The company anticipates application of the technology to any implantable medical device relying on fixation to prevent migration such as AAA stent grafts, septal defect and PFO repair products and embolic devices.
Phase One Medical is initially utilizing both technology platforms in development of two highly differentiated removable vena cava filter systems for the prevention of Pulmonary Embolism (PE) resulting from Deep Vein Thrombosis (DVT). Both systems are safely and easily deployed using jugular and femoral access, are non-tilting and are easily removed when clinically warranted. Both filters will have the capability to treat large vena cava's in excess of 35mm. For physicians who prefer wire guidance, the Tissue Clip(TM) system will utilize a unique over-the-wire delivery system featuring a .035" centering guidewire.
More than 600,000 people develop Deep Venous Thrombosis (DVT) annually with the most serious complication of DVT being Pulmonary Embolism (PE). PE is the third leading cause of acute cardiovascular death in the U.S. resulting in up to 200,000 deaths each year.

BioForm Announces Financial Results for Quarter Ended September 30, 2007, First Quarter of Fiscal 2008

SAN MATEO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- BioForm Medical, Inc. today announced its financial results for the quarter ended September 30, 2007, which is the Company's first quarter of fiscal year 2008. Net sales were $15.2 million for the quarter ended September 30, 2007 as compared to $7.8 million for the quarter ended September 30, 2006, an increase of $7.4 million or 95.1%. The net loss was $3.4 million for the quarter ended September 30, 2007 as compared to $2.3 million for the quarter ended September 30, 2006.

BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm Medical is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm Medical's products include Radiesse(R) dermal filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite(R) injectable implant for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation. BioForm Medical has licensed U.S. marketing rights to Aethoxysklerol(R) sclerotherapy agent, which is the leading worldwide sclerotherapy agent and is currently being evaluated in a Phase III clinical trial. BioForm Medical has also licensed BioGlue(R) surgical adhesive product for plastic surgery applications, which is being developed in a partnership with CryoLife, Inc

full article >> http://money.cnn.com/news/newsfeeds/articles/prnewswire/AQTH05913122007-1.htm

Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million

NATICK, Mass. and NEW YORK, Dec. 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) and Avista Capital Partners, a leading private equity firm, today jointly announced the signing of a definitive agreement under which Avista will acquire from Boston Scientific its Fluid Management and Venous Access businesses for $425 million in cash. The transaction is expected to close in the first quarter of 2008, subject to regulatory approvals and customary conditions. Boston Scientific previously announced its intent to sell these businesses as part of its plan to divest non-strategic assets.
Avista said that upon close of the transaction, the combined Fluid Management/Venous Access business will operate as an independent company under a new name. Ron Sparks, an Avista healthcare industry advisor, will become Chairman and Chief Executive Officer of the new company. Dave McClellan, President of Boston Scientific's Oncology business, will become President of the new company.
The Fluid Management franchise, formerly North American Medical Instruments Corporation (NAMIC), produces a range of products used to manage fluid and measure pressure during angiography and angioplasty procedures. The Fluid Management franchise employs approximately 750 people in its Glens Falls, NY manufacturing facility.

full article >> http://www.globeinvestor.com/servlet/story/PRNEWS.20071213.NETH099/GIStory/

North American Scientific Announces Agreement for Private Placement of Common Stock

CHATSWORTH, Calif.--(BUSINESS WIRE)--North American Scientific, Inc. (Nasdaq: NASI) today announced that on December 12, 2007, North American Scientific, Inc. (the “Company”) entered into a Securities Purchase Agreement with Three Arch Partners IV, L.P. and affiliated funds (“Three Arch Partners”), SF Capital Partners Ltd. (“SF Capital”) and CHL Medical Partners III, L.P. and an affiliated fund (“CHL,” and together with Three Arch Partners and SF Capital, the “Investors”) providing for the private placement (the “Private Placement”) of 63,008,140 shares (the “Shares”) of common stock of the Company, par value $0.01 per share (the “Common Stock”), and warrants to purchase 3,150,407 shares of Common Stock (the “Warrants,” and, together with the Shares, the “Securities”) for a total purchase price of $15.5 million.
North American Scientific is a leader in radiation therapy in the fight against cancer. Its innovative products provide physicians with tools for the treatment of various types of cancers. They include Prospera® brachytherapy seeds and SurTRAK™ needles and strands used primarily in the treatment of prostate cancer. In addition, the Company has been gaining clinical experience with its first generation ClearPath™ multi-channel catheter breast brachytherapy devices in 2007, and intends to launch the second generation devices in 2008. They are the only such devices approved for both high dose and continuous release, or low dose, radiation treatments. The devices are designed to provide flexible, precise dose conformance and an innovative delivery system that is intended to offer the more advanced form of brachytherapy for the treatment of breast cancer. Please visit www.nasmedical.com for more information.

full press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071213006028&newsLang=en

Medicare Changes for Kidney Patients Could be Ahead

The Association of Minority Nephrologists and the National Minority Quality Forum have released a report detailing changes that are currently under consideration from the current U.S. Congress. Lawmakers are discussing altering the current way that Medicare pays for patient care under the End Stage Renal Disease (ESRD) program. Under the status quo program Medicare pays 80 percent of medical costs for an estimated 485,000 ESRD patients. The total payout from Medicare for dialysis, transplants, patient care on both an inpatient and outpatient basis for the ESRD patients is estimated to be around $20 billion. Presently, Medicare reimburses dialysis units at a 'composite rate' that they government sets to cover cost of related supplies and equipment. These facilities then receive a separate payment from Medicare to cover the costs of injectable drugs and diagnostic tests. Congress is considering action to have these two payments grouped together in a new government specified 'bundled rate' for ESRD program participants. The current congress is not the first to consider such a program, starting in the 1990's previous legislatures had researched this cost saving option. However, the research showed that bundling the costs had the possibility of keeping beneficiaries from getting needed medical therapies.

full article >> http://www.associatedcontent.com/article/478255/medicare_changes_for_kidney_patients.html

VeinViewer by Luminetx™ Receives Key Quality and European Certifications

MEMPHIS, Tenn.--(BUSINESS WIRE)--Memphis-based Luminetx Corporation today announced its premier product, VeinViewer by Luminetx™, has received EC and ISO 13485:2003 certifications – thus allowing shipment to European countries and continuing the expansion of the Luminetx global strategy.
The VeinViewer – a vascular imaging system – allows physicians, nurses and other health care professionals to clearly see accessible vasculature (or lack thereof) in real time. The device uses a combination of near-infrared light and patented technologies to image vascular structures and project their location directly on the surface of the skin. This provides clinicians with a safe, non-invasive adjunct technology for clinical treatments and procedures including, but not limited to: IV insertions, PICC line insertions, routine venipuncture (blood sampling), blood and plasma donations and treatment for varicose and spider veins.

full press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071213005152&newsLang=en

PhotoMedex to Supply Lasers Exclusively to AngioDynamics

MONTGOMERYVILLE, Pa.--(BUSINESS WIRE)--PhotoMedex, Inc. (Nasdaq:PHMD) announced today that it will supply private-label diode laser systems exclusively to AngioDynamics, Inc. (Nasdaq: ANGO) to sell and market for peripheral vascular treatments.
In September 2007 AngioDynamics and PhotoMedex entered into a three-year OEM agreement under which PhotoMedex manufactures for AngioDynamics, on a non-exclusive basis, a private-label, 980-nanometer diode laser system. The system is designed for use with AngioDynamics’ NeverTouch™ VenaCure® patented endovenous therapy for treatment of varicose veins. The OEM agreement provides for PhotoMedex to supply this laser on an exclusive basis to AngioDynamics, should AngioDynamics meet certain purchase requirements. With the recent receipt from AngioDynamics of a purchase order that exceeds the minimum purchase requirement for delivery of lasers over the first contract year, PhotoMedex will now provide this laser exclusively to AngioDynamics for worldwide sale in the peripheral vascular treatment field.
Jeffrey O’Donnell, PhotoMedex’ President and Chief Executive Officer, stated, “PhotoMedex has excellent laser development and manufacturing capability that has translated into an OEM agreement that now is exclusive for this 980-nanometer diode laser system for the treatment of vascular diseases and disorders, including varicose veins. Our high standards for quality and reliability were key in attracting AngioDynamics to our diode laser technology. We look forward to a long-term, mutually beneficial relationship.”

full press release >> http://www.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20071213005479&newsLang=en